Q1 Earnings Forecast for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Ionis Pharmaceuticals in a note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($1.18) per share for the quarter. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($1.08) EPS.

Several other equities research analysts have also issued reports on the stock. Citigroup decreased their price target on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday. Piper Sandler cut their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Wells Fargo & Company cut their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Ionis Pharmaceuticals Trading Down 1.1 %

Shares of Ionis Pharmaceuticals stock opened at $32.33 on Monday. The firm has a market capitalization of $5.14 billion, a PE ratio of -10.63 and a beta of 0.34. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. The firm’s 50 day moving average is $33.65 and its 200 day moving average is $38.24. Ionis Pharmaceuticals has a 1 year low of $30.23 and a 1 year high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The firm’s revenue was down 30.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.12 EPS.

Insider Transactions at Ionis Pharmaceuticals

In related news, Director Michael R. Hayden bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $36.22 per share, for a total transaction of $181,100.00. Following the transaction, the director now directly owns 35,219 shares of the company’s stock, valued at approximately $1,275,632.18. The trade was a 16.55 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Patrick R. O’neil sold 6,165 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total transaction of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares in the company, valued at $1,816,632.24. The trade was a 9.69 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,609 shares of company stock worth $3,564,867. Company insiders own 2.71% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IONS. Creative Planning lifted its position in shares of Ionis Pharmaceuticals by 5.7% during the 3rd quarter. Creative Planning now owns 28,382 shares of the company’s stock valued at $1,137,000 after acquiring an additional 1,522 shares during the period. International Assets Investment Management LLC lifted its position in shares of Ionis Pharmaceuticals by 3,287.0% during the 3rd quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock valued at $13,171,000 after acquiring an additional 319,065 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Ionis Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,288 shares of the company’s stock valued at $216,000 after acquiring an additional 930 shares during the period. abrdn plc increased its stake in Ionis Pharmaceuticals by 22.8% during the 3rd quarter. abrdn plc now owns 303,274 shares of the company’s stock valued at $12,064,000 after purchasing an additional 56,357 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Ionis Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,121 shares of the company’s stock valued at $1,127,000 after purchasing an additional 10,971 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.